Of the class I mutation involving activated signaling pathways, FLT3 mutations were the most common concomitant gene mutations in MLL-PTD associated AML, with a frequency of 45% for FLT3-ITD, and up to 58% if FLT3-TKD was included. This evidence concerns the gene FLT3 and acute myeloid leukemia.